Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent
pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the
prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes
contained in the vaccine in adults aged 18 years and older.
“The safety and immunogenicity results from this study suggest that our 20vPnC candidate, which
initiated Phase 3 development in adults last year, could potentially offer comprehensive coverage of
additional serotypes causing pneumococcal disease globally and in the U.S. as substantiated by the
receipt of FDA’s Breakthrough Therapy Designation,” said Kathrin U. Jansen, Ph.D., Senior Vice President
and Head of Vaccine Research & Development, Pfizer. “We believe the full extent of Prevenar 13
protection of adults has yet to be fulfilled. At the same time, there continues to be a global health need
to protect against the potential effects of invasive pneumococcal disease and pneumonia caused by
additional serotypes not yet covered by existing conjugate vaccines.”
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global Combination Vaccine Market Report 2019” @
https://www.businessindustryreports.com/buy-now/171628/single .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Combination Vaccine in these regions, from 2014 to 2023 (forecast),
covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.
The report is a compilation of first-hand information, qualitative and quantitative assessment by
industry analysts, inputs from industry experts and industry participants across the value chain. The
report provides in-depth analysis of parent market trends, macro-economic indicators and governing
factors along with market attractiveness as per segments. The report also maps the qualitative impact of
various market factors on market segments and geographies.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.
Major Points in Table of Contents:
Table of Contents
1 Combination Vaccine Product Definition
2 Global Combination Vaccine Market Manufacturer Share and Market Overview
3 Manufacturer Combination Vaccine Business Introduction
4 Global Combination Vaccine Market Segmentation (Region Level)
5 Global Combination Vaccine Market Segmentation (Product Type Level)